Another Record Revenue Quarter for Orthocell
| Stock | Orthocell Ltd (OCC.ASX) |
|---|---|
| Release Time | 2 Oct 2025, 8:55 a.m. |
| Price Sensitive | Yes |
Orthocell Reports Record Revenue of $3m for September Quarter
- Record revenue of $3.0 million achieved for the quarter ended 30 September 2025
- 9.1% increase over the previous quarterly record of $2.7 million for the June 2025 quarter
- Sixth consecutive quarter of record revenue, with a Compound Quarterly Growth Rate ('CQGR') of 9.5% since product launches in Q2 FY23
Orthocell Limited (ASX:OCC), a regenerative medicine company, has announced a record quarterly revenue result of $3.0 million for the quarter ended 30 September 2025. This result represents a 9.1% increase over the previous quarterly record of $2.7 million for the June 2025 quarter, marking the sixth consecutive quarter of record revenue. The company has achieved a Compound Quarterly Growth Rate (CQGR) of 9.5% since product launches in Q2 FY23. The record revenue performance was primarily driven by increased market penetration of the company's nerve repair product, Remplir, in existing markets, particularly Australia and Singapore. While the result includes a modest but strategically significant financial contribution from early Remplir surgical cases in the US, the anticipated growth in adoption of Remplir by surgeons in the US represents the potential for a material increase in revenue moving forward, expected to build in the December quarter and grow thereafter. Growth in Remplir sales is also expected to be further supplemented by market entry in Canada, with the recent appointment of the first Canadian distributor and initial sales targeted for the December quarter. With circa $27.0 million in cash and no debt, Orthocell is well-positioned to drive rapid product adoption and deliver a step change in revenue in FY26.
Orthocell expects the growth in Remplir sales in the US and Canada to drive a material increase in revenue moving forward, with the anticipated growth in adoption of Remplir by surgeons in the US expected to build in the December 2025 quarter and grow thereafter.
Orthocell is well-positioned to drive rapid product adoption and deliver a step change in revenue in FY26 through the continued growth of Remplir sales in existing markets, as well as the expansion into the US and Canadian markets.